Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransMedics GroupTMDX +2.08%74 Debt-to-Equity is 1.68 as of Jun. 2026, which is 143% above its 10-year median of 0.69. GuruFocus rates TMDX with a GF Score™ of 74/100 and a GF Value™ of $156.12 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 704 Medical Devices & Instruments companies, TransMedics Group ranks worse than 93.32% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TransMedics Group's Debt-to-Equity or its related term are showing as below:
TMDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.18 Med: 0.69 Max: 4.08
Current: 1.68
During the past 10 years, the highest Debt-to-Equity Ratio of TransMedics Group was 4.08. The lowest was -0.18. And the median was 0.69.
TMDX's Debt-to-Equity is ranked worse than 93.32% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs TMDX: 1.68
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TransMedics Group Debt-to-Equity Related Terms
TransMedics Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TransMedics Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMDX vs ESTA, AXGN, NVCR: Debt-to-Equity Comparison
For the Medical Devices subindustry, TransMedics Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TransMedics Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (TMDX) has a Debt-to-Equity of 1.68 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TransMedics Group and its competitors. This is 143% above median its historical median of 0.69. According to the industry distribution chart, TransMedics Group ranks #657 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 93.3%.
Is TransMedics Group's Debt-to-Equity too high?
TransMedics Group's current Debt-to-Equity of 1.68 is 143% above median its 10-year median of 0.69. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. TransMedics Group's value of 1.68 is 630.4% above this industry median. Based on the distribution chart, TransMedics Group ranks #657 out of 704 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Debt-to-Equity compare to ESTA and AXGN?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #657 out of 704 companies for Debt-to-Equity. This places TransMedics Group in the lower half of its industry. The industry median Debt-to-Equity is 0.23. TransMedics Group's value of 1.68 is 630.4% above this benchmark. While the company's 10-year median is 0.69 vs. the industry median of 0.23, TransMedics Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current Debt-to-Equity of 1.68 is 630.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current Debt-to-Equity is 1.68, which is 143% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $156.12, compared to a current price of $88.83 — trading 43.1% below its estimated fair value. The current Debt-to-Equity is 1.68, which is 143% above median its 10-year median of 0.69 and 630.4% above the Medical Devices & Instruments industry median of 0.23. TransMedics Group's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TransMedics Group (TMDX), the current Debt-to-Equity is 1.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $88.83 is trading 43.1% below its estimated GF Value™ of $156.12.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
Debt-to-Equity: 1.68 (143% above median its 10-year median of 0.69)
GF Value™: $156.12 vs. price of $88.83 (43.1% below fair value)
Industry Position: 630.4% above the Medical Devices & Instruments median (#657 of 704)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
74GF Score
Get the complete analysis for TMDX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
